Overview

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Status:
Completed

Trial end date:
2018-07-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol treated with maximally tolerated statin therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Esperion Therapeutics
Esperion Therapeutics, Inc.

Treatments:

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Ezetimibe